AT-527 has demonstrated clinical tolerability and potent antiviral activity in patients with HCV infection, as well as a favorable human pharmacokinetic (PK) profile. With potent in vitro activity against human coronaviruses, AT-527 is now being evaluated for treatment of COVID-19 patients.
Well-tolerated in 28 HCV-infected patients who received a QD (once daily) dose of 550 mg of AT-527 for 7 days or up to 12 weeks.
High solubility promotes rapid absorption.
Designed for QD or BID (twice daily) oral administration.
Increases the shelf life of therapeutics.